Maevena
Openfederal funding•Federal coverage•Tier 2 intelligence

A grant from HHS-NIH11

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Grant

This NCI R01 opportunity focuses on research in patients receiving cancer therapy that integrates imaging with fluid-based tumor monitoring/liquid biopsy to determine their optimal use in characterizing treatment…

Official application

Award

Up to $500,000

Deadline

January 7, 2028

447 days

Apply at official source Check your eligibility

No signup · Source checked 10/16/2026

Decision snapshot

Potential award

Up to $500,000

Official deadline

January 7, 2028

447 days

Eligibility evidence

2 confirmed criteria

5 checks available

Application load

Moderate effort

01

Start here

Confirm eligibility

Check your fit in about 60 seconds.

Eligibility requirementsQuestion 1 of 5
About 60 seconds totalConfirmed criterion

Does your organization have the required nonprofit status?

What does this mean?

Eligible nonprofits are named in the source requirements.

Review supporting source ↗
Does your organization have the required nonprofit status?
Select an answer to continue

No signup · Answers stay in this browser session

This is an explainable self-assessment, not a win probability or legal determination. Hard eligibility conflicts are never averaged against softer program-fit signals. Always verify the official notice.

Optional Review source criteria and citations

Nonprofit status

Eligible nonprofits are named in the source requirements.

Review source ↗
confirmed

Geography

Nationwide availability is inferred from the catalog record; confirm the official notice.

Review source ↗
inferred

Organization size

No organization-size limit was captured.

Review source ↗
unclear

Program area

Education, Health, Human Services, Research

Review source ↗
inferred

Population served

No specific population was captured.

Review source ↗
unclear

Matching funds

No cost share is indicated.

Review source ↗
confirmed

Registrations

SAM.gov and Grants.gov registration may be required; confirm in the notice.

Review source ↗
inferred

Exclusions

Review the full notice for exclusions and prohibited uses.

Review source ↗
unclear
02

Grant-writer assessment

Understand the opportunity

Start with the practical interpretation. Open the complete source narrative when you need the underlying detail.

Plain-English explanation

Plain-English explanation

This NCI R01 opportunity focuses on research in patients receiving cancer therapy that integrates imaging with fluid-based tumor monitoring/liquid biopsy to determine their optimal use in characterizing treatment response and/or emerging resistance. Organizational eligibility is broad, but foreign organizations and non-U.S. components of U.S. organizations are excluded. The record lists a $500,000 award ceiling, no required cost sharing, and a January 7, 2028 deadline; the ceiling’s application and the deadline time and timezone require confirmation in PAR-25-175.

Editorial analysis

What the funder is trying to accomplish

NCI seeks research projects that integrate imaging and liquid-biopsy assays during cancer therapy in patients to determine the optimal use of those modalities for characterizing therapy response, the emergence of resistance, or both.

Editorial analysis

Strong-fit project signals

The proposed project directly studies patients while they are receiving cancer therapy rather than limiting the work to preclinical models or assay development detached from treatment monitoring. Imaging and fluid-based tumor-monitoring/liquid-biopsy assays are integrated components of the same research project rather than separate or optional subprojects. The project is designed to determine the optimal use of the modalities for characterizing therapy response, the emergence of resistance, or both. The applicant falls within a listed organizational category and is neither a foreign organization nor a non-U.S. component of a U.S. organization. The proposed budget is consistent with the listed $500,000 award ceiling, subject to confirmation of how that ceiling applies; cost sharing is not required.

Editorial analysis

What reviewers may prioritize

The evidence packet does not provide formal review criteria. Based on the program description, likely scientific priorities include coherent integration of imaging and liquid biopsy in patients, a direct connection to cancer therapy, and a design that can determine how the modalities characterize response or emerging resistance. These are scope-based inferences, not confirmed scoring criteria.

Source dossier Read the full official program description
Source-backed synopsis

What this grant funds

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance.

Read the complete official description ↗
03

Decision economics

Size the opportunity

Use the source facts below to judge whether the likely return justifies the application effort.

Award range
Up to $500,000
Total program funding
$500,000
Expected awards
Not specified
Geography
National
Cost share
Not indicated
Assistance listing
Not specified

Mission alignment

Compare your program with Education, Health, Human Services.

Geographic fit

National

04

Working plan

Build the application

The generated milestones are planning aids. Only the official notice establishes required dates.

Requirements captured

Other requirements
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Submission system
Grants.gov
Attachments
https://grants.nih.gov/grants/guide/pa-files/PAR-25-175.html, PAR-25-175 Full Announcement Text
Contact
National Institutes of Health · grantsinfo@nih.gov · 301-402-2541

Official deadline

January 7, 2028

Moderate effort based on requirements currently captured.

  1. Confirm eligibility, registrations, partners, and internal approval.

  2. Finalize project design, outcomes, and supporting evidence.

  3. Draft the narrative and detailed budget.

  4. Complete compliance review and collect attachments.

  5. Submit early and preserve the confirmation receipt.

05Past behaviorCompare historical awardsHistorical patterns provide context, but do not predict or guarantee future funding decisions.
No licensed historical awards are currently linked to this opportunity.
06Audit trailVerify the evidenceSee where the facts came from, when they were checked, and what has materially changed.

Source record

What “source verified” means

The official record was successfully checked. Verification does not mean every eligibility or application field has been extracted. Read the methodology →

Verification
verified
Source
grants gov
Last checked
10/16/2026, 1:17:13 PM
Content updated
10/16/2026, 1:42:00 PM
Review
Automated normalization; not yet expert-reviewed
Open official source ↗

Material changes

  1. Updated eligibility, eligibility details.

  2. Updated eligibility, eligibility details.

  3. Updated eligibility, eligibility details.

  4. Updated eligibility, eligibility details.

  5. Updated eligibility, eligibility details.

  6. Updated eligibility, eligibility details.

  7. Updated eligibility, eligibility details.

  8. Updated eligibility, eligibility details.

  9. Updated eligibility, eligibility details.

  10. Updated eligibility, eligibility details.

  11. Updated eligibility, eligibility details.

  12. Updated eligibility, eligibility details.

Verify before applying. Official funder documents control. Derived analysis and preparation dates should not replace the notice.
Keep searchingSimilar and alternative grantsExplore verified opportunities related by program area, funder, or funding type.

HHS-OPHS

Making America Healthy Again by Addressing Dementia Disparities

Related by Health and Human Services.

View grant →

HHS-HRSA

Fiscal Year 2027 Regional Nutrition Hubs

Related by Health and Human Services.

View grant →

HHS-NIH11

Digital Health Technology and Reciprocal Innovation to Improve Clinical and Public Health Outcomes

Related by Health and Human Services.

View grant →

HHS-NIH11

Extracellular Vesicle Therapeutics for Regenerative Medicine (ExTReMe)

Related by Health and Human Services.

View grant →

HHS-NIH11

Research on System Support and Tools for Provider Training and Quality Monitoring for Suicide Preventive Care

Related by Health and Human Services.

View grant →

DOD-AMC-ACCRI

Broad Agency Announcement for Fundamental AI Research

Related by Research.

View grant →
Quick answersFrequently asked questionsGet concise answers about Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Grant.
Is Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Grant currently open?

Yes, based on the latest source record. The deadline is January 7, 2028, with 447 days remaining. Because funders can amend or extend notices, confirm the date and submission instructions on the official application page. The source was last checked 10/16/2026.

How much funding does Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Grant provide?

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Grant lists Up to $500,000 per award. The total program funding recorded is $500,000. The expected number of awards has not been captured, so the award range alone should not be treated as an estimate of competitiveness.

Who can apply to Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Grant?

Others (see text field entitled "Additional Information on Eligibility" for clarification); Public and State controlled institutions of higher education; Special district governments; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; County governments;… Applicants should still complete the eligibility quiz and verify every condition in the official notice; a general fit does not override exclusions or registration requirements.

Does Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Grant require matching funds?

No cost-share requirement is indicated in the captured source facts. Applicants should still verify the official budget instructions in case an amendment, program track, or specific cost category carries additional conditions.

What should I prepare before applying to Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) Grant?

Moderate effort is expected. The captured requirements include other requirements, submission system, attachments, contact. Start by confirming eligibility and registrations, then work backward from January 7, 2028 using the preparation plan above.